Whole genome sequencing with comprehensive re-analysis in undiagnosed or unclear causes with mitochondrial dysfunction: How this can lead to improved diagnosis, treatment, and clinical outcomes.

Episode 58 November 05, 2021 01:27:22
Whole genome sequencing with comprehensive re-analysis in undiagnosed or unclear causes with mitochondrial dysfunction: How this can lead to improved diagnosis, treatment, and clinical outcomes.
MitoAction Expert Series
Whole genome sequencing with comprehensive re-analysis in undiagnosed or unclear causes with mitochondrial dysfunction: How this can lead to improved diagnosis, treatment, and clinical outcomes.

Nov 05 2021 | 01:27:22

/

Show Notes

Join MitoAction and Dr. Richard Boles for our November Mito Expert Series presentation titled: Whole genome sequencing with comprehensive re-analysis in undiagnosed or unclear causes with mitochondrial dysfunction: How this can lead to improved diagnosis, treatment, and clinical outcomes.

Dr. Boles will talk with us about the Neurabilities NeuroGenomics Program and how we can make exact diagnoses using whole genome sequencing, translate that into treatments, and improve clinical outcomes. He will also share information with us about the NeuroNeeds product line.

Click here for the accompanying slides.

Other Episodes

Episode 0

August 07, 2020 01:04:39
Episode Cover

IEP Considerations for Students with Mitochondrial Disorders - Gena Padgett - 8/7/2020

Join MitoAction and Gena Padgett, a licensed school psychologist for our August Monthly Mito Expert Series presentation titled IEP Considerations for Students with Mitochondrial...

Listen

Episode

June 22, 2022 01:01:59
Episode Cover

Q&A with Compounding Pharmacists

One of the front-line treatment approaches to mitochondrial disease is use of a combination, unique to each patient based on symptoms and diagnosis, of...

Listen

Episode

March 12, 2025 01:02:47
Episode Cover

Expert Series: Ceramides: The Unmasked Drivers of VLCADD-Induced Heart Failure

Despite advances in newborn screening and treatment of fatty acid oxidation disorders, patients with very-long-chain acyl-CoA dehydrogenase deficiency (VLCADD) continue to suffer from heart...

Listen